Ingredion Incorporated announced that Univar Solutions LLC will serve as the exclusive distributor of its Pharma Solutions portfolio in the United States and Canada. The partnership gives Univar access to Ingredion’s range of functional excipients—binders, fillers, superdisintegrants, lubricants, and gelatin replacements—used in tablet and capsule manufacturing.
The deal expands Ingredion’s footprint in the pharmaceutical and nutraceutical markets, allowing the company to reach a broader customer base through Univar’s established distribution network. Univar’s expertise in specialty ingredients, including formulation support, regulatory compliance, and a global supply‑chain footprint, positions it as an ideal partner for delivering Ingredion’s excipient technologies to clean‑label and vegetarian formulations that are driving demand in the industry.
Ingredion’s strategy to grow its high‑margin specialty‑ingredient business is reinforced by this agreement. The company has recently invested in India, acquiring Amishi Drugs & Chemicals and Mannitab Pharma Specialities, and has been building a portfolio that serves a nearly $1.5 billion global market for pharmaceutical‑grade ingredients. By partnering with Univar, Ingredion can accelerate adoption of its excipients and strengthen its competitive position in a market that is expanding as manufacturers seek innovative, clean‑label solutions.
The partnership is expected to broaden Ingredion’s customer reach and accelerate sales of its Pharma Solutions portfolio. While specific financial targets are not disclosed, the agreement aligns with Ingredion’s broader goal of diversifying revenue beyond its core food and industrial segments and capturing a larger share of the specialty‑ingredient market.
Management has emphasized the importance of higher‑value solutions in recent guidance. CEO Jim Zallie has highlighted the company’s focus on leveraging its global network and adapting quickly to shifting demand, underscoring the strategic intent behind the Univar partnership.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.